Clinical trials
4 active studies led by Prime Medicine, Inc., of 4 in all
Source: ClinicalTrials.gov, Studies with Prime Medicine, Inc. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
- 0Reports naming them
- 1Markets in public records
- 0Regions & countries
- 4Active trials they lead[1]
[1] ClinicalTrials.gov, Studies led by Prime Medicine, Inc. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
Free public data on Prime Medicine, Inc.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
Company facts
- Stock listing
- NASDAQ: PRME
- Type
- Medicines
Source: SEC EDGAR, Company filings, CIK 1894562. Retrieved 13 Nov 2026.
See them on ClinicalTrials.gov (opens in a new tab)
SEC filings
Annual reports and other filings with the US Securities and Exchange Commission.
Source: SEC EDGAR, Company filings, CIK 1894562.
Trials over time
Studies Prime Medicine, Inc. leads, by the year they started and their phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- No phase (devices, observational)
Source: ClinicalTrials.gov, Studies with Prime Medicine, Inc. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets where public records show them
Markets we cover where free public records show Prime Medicine, Inc.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
Topics
The topics of the markets Prime Medicine, Inc. is in.
From our blog
Stories on the topics Prime Medicine, Inc. works in.
Patient Support Programmes: Helping Patients Stay on Treatment
WHO says only about half of patients in developed countries take long-term medicines as prescribed. Patient…
Read
Biologic Safety Testing: The Quiet Backbone of Drug Making
Every vaccine, antibody and cell therapy must be tested for sterility, purity and viruses before it reaches…
Read
Cell-Based Immunotherapy: Promise and Price
The first CAR-T cell therapy was approved in the US in August 2017. These living drugs can work when other…
Read